Profiles

Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Ali Keshavarzian and Ece Mutlu.

 
Connection Strength
 
 
 
5.633
 
  1. Keshavarzian A, Mutlu EA. Complementary and Alternative Treatments Are Needed to Enhance the Care of the Inflammatory Bowel Disease Patient. Gastroenterol Clin North Am. 2017 12; 46(4):xiii-xiv.
    View in: PubMed
    Score: 0.873
  2. Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, Kwasny M, Lau CK, Keshavarzian A. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol. 2012 May 01; 302(9):G966-78.
    View in: PubMed
    Score: 0.587
  3. Mutlu EA, Farhadi A, Keshavarzian A. New developments in the treatment of inflammatory bowel disease. Expert Opin Investig Drugs. 2002 Mar; 11(3):365-85.
    View in: PubMed
    Score: 0.296
  4. Rasmussen HE, Hamaker B, Rajan KB, Mutlu E, Green SJ, Brown M, Kaur A, Keshavarzian A. Starch-entrapped microsphere fibers improve bowel habit but do not exhibit prebiotic capacity in those with unsatisfactory bowel habits: a phase I, randomized, double-blind, controlled human trial. Nutr Res. 2017 Aug; 44:27-37.
    View in: PubMed
    Score: 0.213
  5. Engen PA, Dodiya HB, Naqib A, Forsyth CB, Green SJ, Voigt RM, Kordower JH, Mutlu EA, Shannon KM, Keshavarzian A. The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. J Parkinsons Dis. 2017; 7(2):331-346.
    View in: PubMed
    Score: 0.207
  6. Yazici C, Arslan DC, Abraham R, Cushing K, Keshavarzian A, Mutlu EA. Breath Methane Levels Are Increased Among Patients with Diverticulosis. Dig Dis Sci. 2016 09; 61(9):2648-54.
    View in: PubMed
    Score: 0.198
  7. Shobar RM, Velineni S, Keshavarzian A, Swanson G, DeMeo MT, Melson JE, Losurdo J, Engen PA, Sun Y, Koenig L, Mutlu EA. The Effects of Bowel Preparation on Microbiota-Related Metrics Differ in Health and in Inflammatory Bowel Disease and for the Mucosal and Luminal Microbiota Compartments. Clin Transl Gastroenterol. 2016 Feb 11; 7:e143.
    View in: PubMed
    Score: 0.195
  8. Miller GE, Engen PA, Gillevet PM, Shaikh M, Sikaroodi M, Forsyth CB, Mutlu E, Keshavarzian A. Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults. PLoS One. 2016; 11(2):e0148952.
    View in: PubMed
    Score: 0.195
  9. Patel AL, Mutlu EA, Sun Y, Koenig L, Green S, Jakubowicz A, Mryan J, Engen P, Fogg L, Chen AL, Pombar X, Meier PP, Keshavarzian A. Longitudinal Survey of Microbiota in Hospitalized Preterm Very-Low-Birth-Weight Infants. J Pediatr Gastroenterol Nutr. 2016 Feb; 62(2):292-303.
    View in: PubMed
    Score: 0.194
  10. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015 Sep; 30(10):1351-60.
    View in: PubMed
    Score: 0.187
  11. Couch RD, Dailey A, Zaidi F, Navarro K, Forsyth CB, Mutlu E, Engen PA, Keshavarzian A. Alcohol induced alterations to the human fecal VOC metabolome. PLoS One. 2015; 10(3):e0119362.
    View in: PubMed
    Score: 0.183
  12. Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol. 2014 Nov 07; 20(41):15358-66.
    View in: PubMed
    Score: 0.178
  13. Voigt RM, Forsyth CB, Green SJ, Mutlu E, Engen P, Vitaterna MH, Turek FW, Keshavarzian A. Circadian disorganization alters intestinal microbiota. PLoS One. 2014; 9(5):e97500.
    View in: PubMed
    Score: 0.173
  14. Mutlu EA, Keshavarzian A, Losurdo J, Swanson G, Siewe B, Forsyth C, French A, Demarais P, Sun Y, Koenig L, Cox S, Engen P, Chakradeo P, Abbasi R, Gorenz A, Burns C, Landay A. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014 Feb; 10(2):e1003829.
    View in: PubMed
    Score: 0.170
  15. Couch RD, Navarro K, Sikaroodi M, Gillevet P, Forsyth CB, Mutlu E, Engen PA, Keshavarzian A. The approach to sample acquisition and its impact on the derived human fecal microbiome and VOC metabolome. PLoS One. 2013; 8(11):e81163.
    View in: PubMed
    Score: 0.167
  16. Yazici C, Losurdo J, Brown MD, Oosterveen S, Rahimi R, Keshavarzian A, Bozorgnia L, Mutlu E. Inpatient capsule endoscopy leads to frequent incomplete small bowel examinations. World J Gastroenterol. 2012 Sep 28; 18(36):5051-7.
    View in: PubMed
    Score: 0.154
  17. Mutlu EA, Engen PA, Soberanes S, Urich D, Forsyth CB, Nigdelioglu R, Chiarella SE, Radigan KA, Gonzalez A, Jakate S, Keshavarzian A, Budinger GR, Mutlu GM. Particulate matter air pollution causes oxidant-mediated increase in gut permeability in mice. Part Fibre Toxicol. 2011 Jun 09; 8:19.
    View in: PubMed
    Score: 0.141
  18. Gillevet P, Sikaroodi M, Keshavarzian A, Mutlu EA. Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers. 2010 May; 7(5):1065-75.
    View in: PubMed
    Score: 0.130
  19. Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res. 2009 Oct; 33(10):1836-46.
    View in: PubMed
    Score: 0.124
  20. Keefer L, Keshavarzian A, Mutlu E. Reconsidering the methodology of "stress" research in inflammatory bowel disease. J Crohns Colitis. 2008 Sep; 2(3):193-201.
    View in: PubMed
    Score: 0.112
  21. Keshavarzian A, Mutlu E, Guzman JP, Forsyth C, Banan A. Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs. 2007 Sep; 16(9):1489-506.
    View in: PubMed
    Score: 0.108
  22. Komanduri S, Gillevet PM, Sikaroodi M, Mutlu E, Keshavarzian A. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol. 2007 Mar; 5(3):352-60.
    View in: PubMed
    Score: 0.105
  23. Kaplan M, Mutlu EA, Benson M, Fields JZ, Banan A, Keshavarzian A. Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders. Complement Ther Med. 2007 Sep; 15(3):207-16.
    View in: PubMed
    Score: 0.101
  24. Mutlu EA, Keshavarzian A, Mutlu GM. Hyperalbuminemia and elevated transaminases associated with high-protein diet. Scand J Gastroenterol. 2006 Jun; 41(6):759-60.
    View in: PubMed
    Score: 0.099
  25. Kaplan M, Mutlu EA, Jakate S, Bruninga K, Losurdo J, Losurdo J, Keshavarzian A. Endoscopy in eosinophilic esophagitis: "feline" esophagus and perforation risk. Clin Gastroenterol Hepatol. 2003 Nov; 1(6):433-7.
    View in: PubMed
    Score: 0.083
  26. Kaur A, Chen T, Green SJ, Mutlu E, Martin BR, Rumpagaporn P, Patterson JA, Keshavarzian A, Hamaker BR. Physical Inaccessibility of a Resistant Starch Shifts Mouse Gut Microbiota to Butyrogenic Firmicutes. Mol Nutr Food Res. 2019 04; 63(7):e1801012.
    View in: PubMed
    Score: 0.060
  27. Dillon SM, Guo K, Austin GL, Gianella S, Engen PA, Mutlu EA, Losurdo J, Swanson G, Chakradeo P, Keshavarzian A, Landay AL, Santiago ML, Wilson CC. A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis. AIDS. 2018 Jul 31; 32(12):1599-1611.
    View in: PubMed
    Score: 0.058
  28. Gianella S, Chaillon A, Mutlu EA, Engen PA, Voigt RM, Keshavarzian A, Losurdo J, Chakradeo P, Lada SM, Nakazawa M, Landay AL. Effect of cytomegalovirus and Epstein-Barr virus replication on intestinal mucosal gene expression and microbiome composition of HIV-infected and uninfected individuals. AIDS. 2017 09 24; 31(15):2059-2067.
    View in: PubMed
    Score: 0.054
  29. Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017 Jun 30; 127(7):2829-2841.
    View in: PubMed
    Score: 0.053
  30. Voigt RM, Keshavarzian A, Losurdo J, Swanson G, Siewe B, Forsyth CB, French AL, Demarais P, Engen P, Raeisi S, Mutlu E, Landay AL. HIV-associated mucosal gene expression: region-specific alterations. AIDS. 2015 Mar 13; 29(5):537-46.
    View in: PubMed
    Score: 0.046
  31. Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Fleshner P, Stappenbeck TS, McGovern DP, Keshavarzian A, Mutlu EA, Sauk J, Gevers D, Xavier RJ, Wang D, Parkes M, Virgin HW. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015 Jan 29; 160(3):447-60.
    View in: PubMed
    Score: 0.045
  32. Wisittipanit N, Rangwala H, Sikaroodi M, Keshavarzian A, Mutlu EA, Gillevet P. Classification methods for the analysis of LH-PCR data associated with inflammatory bowel disease patients. Int J Bioinform Res Appl. 2015; 11(2):111-29.
    View in: PubMed
    Score: 0.045
  33. Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015 Jan; 148(1):203-214.e16.
    View in: PubMed
    Score: 0.044
  34. Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2012 May; 27(6):709-15.
    View in: PubMed
    Score: 0.035
  35. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol. 2002 Apr; 34(4):385-96.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.